Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...
Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...
Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...
Analysts for William Blair and BTIG initiated coverage of Alpha Teknova (NASDAQ:TKNO) with “outperform” and “buy” ratings, respectively, citing the company’s exposure to several large, rapidly growing markets. “In...
SVB Leerink launched coverage of Elevation Oncology (NASDAQ:ELEV) with an “outperform” rating and $20 price target. The stock closed at $12.10 on July 19. Elevation is a clinical development-stage biotech company...
William Blair launched coverage of Talkspace (NASDAQ:TALK) with an “outperform” rating, pointing to the company’s platform and significant market opportunity. The stock closed at $5.81 on July 16. “We believe the...
Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15. Immutep has a pipeline of...
Canaccord Capital upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “hold” and raised its price target to $18 from $11, citing the company’s pre-announcement of second quarter results, which “illustrate early signs of...
Cantor Fitzgerald initiated coverage of Novan (NASDAQ:NOVN) with an “overweight” rating and $30 price target. The stock closed at $9.10 on July 8. Novan is a clinical-stage biotechnology company focused on leveraging...
SVB Leerink launched coverage of F-Star Therapeutics (NASDAQ:FSTX) with an “outperform” rating and $39 price target. The stock closed at $7.34 on July 7. F-star’s pipeline generates drug candidates that work with...